BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » mesenchymal stem cells » Page 5

Do You Know What Regions are Doing the Most Searches for Mesenchymal Stem Cells (MSCs)?

April 7, 2016 By Cade Hildreth (CEO) Leave a Comment

Do You Know What Regions are Doing the Most Searches for Mesenchymal Stem Cells (MSCs)?

Google Trends is a supplemental service of Google Incorporated that analyzes trend data collected through Google Search.

It shows how often a particular search term is entered relative to total search-volume across various regions of the world and in various languages.

It is an absolutely incredible market research tool for assessing stem cell market dynamics, because it reflects real-time social behavior related to specific stem cell types and provides public access to Google’s online search information. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: Google, market metrics, mesenchymal stem cells, trends

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

April 7, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD).  This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”.  Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]

Filed Under: Stem Cells Tagged With: cynata therapeutics, manufacturing, mesenchymal stem cells, press release

What Types of Mesenchymal Stem Cell (MSC) Research Are Getting Funded?

March 23, 2016 By Cade Hildreth (CEO) Leave a Comment

2015 Fiscal Year Grants Awarded by the NIH to Support MSC Research Projects

To analyze trends within the mesenchymal stem cell (MSC) industry, it is valuable to consider grant rate data. Previously, the U.S. federal government operated an online tool called CRISP (“Computer Retrieval of Information on Scientific Projects”). It was a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other U.S. research institutions. The database allowed users to search the CRISP interface for grants funding for specific types of scientific research, using text-based search terms.

However, that has since been replaced by RePORTer (Research Portfolio Online Reporting Tools)1, a more powerful database and search tool supported by the U.S. Department of Health and Human Services. RePORTer allows users to search a comprehensive repository of National Institutes of Health (NIH) funded research projects resulting from NIH funding. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: funding, mesenchymal stem cells, mesenchymal stromal cells, NIH, research

Current Bottlenecks in MSC Research: Widespread MSC Misconceptions

March 19, 2016 By Cade Hildreth (CEO) Leave a Comment

Current Bottlenecks in MSC Research: Widespread MSC Misconceptions - Myths or Facts Concept

This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.


We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation.  While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back.  [Read more…]

Filed Under: MSCs Tagged With: Cytotherapy, Jon Rowley, mesenchymal stem cells, RoosterBio

Cynata Therapeutics Enters Agreement for Strategic Alliance with Regience K.K. in Japan

March 3, 2016 By Cade Hildreth (CEO) Leave a Comment

Cynata Therapeutics Enters Agreement for Strategic Alliance with Regience K.K. in Japan

In recently released news, Cynata Therapeutics announced that it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and certain other Asian countries.

Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) derived from a one-time donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. This approach allows MSCs to be produced in nearly limitless quantities, eliminates product variability, and allows for lower manufacturing costs.

Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw.  To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: cell therapy, cynata therapeutics, mesenchymal stem cells, press release, Regience K.K.

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 12
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.